Product Information
PROPAFENONE HCL ER 325 MG CAP is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.5711 per EA under NDC 69680013160. Its NADAC has been published 398 times since Feb 20, 2019.
FDA first approved this application on Jan 4, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
325 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680013160
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PROPAFENONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210339FDA Approved
1/4/2019
TE Code
AB
On Market Since
1/28/2019
Pharmacological Classes
Price Statistics
The NADAC for PROPAFENONE HCL ER 325 MG CAP has been published 398 times since Feb 20, 2019, and over the history we have for it it has declined 84.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5711 per EA |
|---|---|
| All-time high | $4.5892 (Apr 15, 2020) |
| All-time low | $0.4264 (Feb 18, 2026) |
| 52-week high | $0.6559 |
| 52-week low | $0.4264 |
| Median price | $1.2732 |
| Average price | $1.7230 |
| Largest weekly change | +97.6% (Oct 20, 2021) |
| Weeks tracked | 398 |
| Tracking since | Feb 20, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the propafenone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
propafenone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROPAFENONE HCL ER 325 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for PROPAFENONE HCL ER 325 MG CAP, manufactured by Vitruvias Therapeutics Inc., is $0.5711 per EA (NDC 69680013160), effective Sep 30, 2026.
How has the price of PROPAFENONE HCL ER 325 MG CAP changed over time?
Over the history we have for it, the NADAC for PROPAFENONE HCL ER 325 MG CAP has declined 84.2%. It has been tracked across 398 weekly CMS publications since Feb 20, 2019.
What are the highest and lowest recorded NADAC prices for PROPAFENONE HCL ER 325 MG CAP?
Since Feb 20, 2019, the NADAC for PROPAFENONE HCL ER 325 MG CAP has ranged from a low of $0.4264 (Feb 18, 2026) to a high of $4.5892 (Apr 15, 2020), with a median of $1.2732 per EA.
Are there cheaper alternatives to PROPAFENONE HCL ER 325 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of PROPAFENONE HCL ER 325 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PROPAFENONE HCL ER 325 MG CAP?
PROPAFENONE HCL ER 325 MG CAP (NDC 69680013160) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.